Clinical Research Directory
Browse clinical research sites, groups, and studies.
Relmacabtagene Autoleucel in Hematologic Malignancies
Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
Summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Official title: A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2023-12-28
Completion Date
2038-12-31
Last Updated
2023-11-21
Healthy Volunteers
No
Interventions
Relmacabtagene Autoleucel
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Locations (2)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University International Hospital
Beijing, Beijing Municipality, China